
11 - 50 employees
Founded 2008
🏥 Healthcare
💼 Consulting
🎖️ Defense
💰 $200M Post-IPO Equity - Immuneering on 2025-09
Healthcare • Consulting • Defense
Immuneering Corporation is a clinical-stage biotechnology company developing a novel class of oncology therapies called Deep Cyclic Inhibitors, which use rhythmic dosing to outpace cancer adaptation, improve tolerability, and extend patient survival and quality of life. The company advances a pipeline through clinical trials, collaborates with partners, and emphasizes scientific research and publications to transform cancer treatment while reducing side effects of traditional continuous-inhibition therapies.
Selected: 🆕 Date Added.
🕒 September 22
Associate Director overseeing solid oral drug formulation, process development and CDMO manufacturing at Immuneering, a clinical-stage oncology biopharmaceutical company.
🏄 California, New York, +1 more states – Remote
💵 $170k - $210k / year
💰 $200M Post-IPO Equity - Immuneering on 2025-09
⏰ Full Time
🟠 Senior
👔 Director
👻 Ghost score 0%
🕒 September 2
Regulatory CMC Director leading global submissions and regulatory strategy for Immuneering's oncology therapies. Guiding CMC development, agency interactions, and product lifecycle management.
🏄 California, New York, +1 more states – Remote
💵 $235k - $270k / year
💰 $200M Post-IPO Equity - Immuneering on 2025-09
⏰ Full Time
🔴 Lead
🚔 Compliance
👻 Ghost score 2%
🕒 July 9
Director of Pharmacovigilance at Immuneering leading safety surveillance strategies across oncology programs. Building the PV function at a clinical-stage biopharmaceutical company.
🇺🇸 United States – Remote
💵 $280k - $350k / year
💰 $200M Post-IPO Equity - Immuneering on 2025-09
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 26%